Sermorelin is a synthetic 29-amino acid peptide representing the fully functional amino-terminal segment of endogenous growth hormone-releasing hormone (GHRH). Formulated exclusively for laboratory research, this compound serves as an essential tool for evaluating pituitary somatotroph signaling, receptor activation dynamics, and pulsatile growth hormone secretion in preclinical models.
Sermorelin is a synthetic 29-amino acid peptide representing the fully functional amino-terminal segment of endogenous growth hormone-releasing hormone (GHRH). Formulated exclusively for laboratory research, this compound serves as an essential tool for evaluating pituitary somatotroph signaling, receptor activation dynamics, and pulsatile growth hormone secretion in preclinical models.
A sermorelin research compound is a synthetic peptide fragment corresponding to the naturally occurring sequence GHRH(1-29)-NH2. Containing the active amino-terminal sequence of human growth hormone-releasing hormone, Sermorelin retains full biological activity at the GHRH receptor while possessing a lower molecular weight than the full-length 44-amino acid endogenous ligand. In laboratory settings, it is utilized as a standard reference agonist to investigate pituitary receptor binding kinetics and neuroendocrine signaling pathways.
The primary sequence of Sermorelin consists of 29 amino acid residues with a amidated C-terminus: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Molecular weight verification by high-resolution mass spectrometry typically confirms a mass of 3357.9 Da. Because the N-terminal sequence contains the specific domain required for receptor activation, this 1-29 truncated peptide maintains high binding affinity for the growth hormone-releasing hormone receptor (GHRH-R) on anterior pituitary somatotrophs.
Researchers studying peptide structure-activity relationships rely on sermorelin due to its reproducible conformation in physiological buffers. When handling lyophilized samples, verifying the amino acid composition and sequence fidelity is critical for avoiding baseline experimental variance in cell culture and cell-free binding assays.
At the cellular level, the primary mechanism of action for the sermorelin research compound involves selective binding to the GHRH receptor, a seven-transmembrane domain G-protein coupled receptor (GPCR) primary expressed in the anterior pituitary gland. Upon ligand binding, the receptor undergoes a conformational change that activates the stimulatory G-protein alpha subunit (Gs-alpha).
Activation of Gs-alpha directly stimulates membrane-bound adenylyl cyclase, initiating the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP concentrations activate Protein Kinase A (PKA), which subsequently phosphorylates specific transcription factors, including the cAMP response element-binding protein (CREB). CREB activation leads to enhanced transcription of the growth hormone gene and associated regulatory factors.
Simultaneously, intracellular signaling assays in preclinical pituitary cell lines demonstrate that GHRHR activation leads to an influx of extracellular calcium through voltage-gated L-type calcium channels, as well as the release of intracellular calcium stores via the inositol trisphosphate (IP3) pathway. This rapid elevation of cytosolic free calcium promotes the exocytosis of pre-stored growth hormone secretory vesicles. Understanding these dual cAMP/calcium pathways helps researchers delineate downstream metabolic and gene expression responses in preclinical research models.
In vitro and animal model studies consistently indicate that Sermorelin preserves the native physiological feedback loops governing axis regulation. Unlike direct growth hormone administration, GHRH analogs rely on intact pituitary somatotroph populations, making them valuable reference standards for investigating pituitary functional capacity.
Preclinical rodent and non-human primate studies demonstrate that administration of GHRH(1-29) induces a rapid, concentration-dependent surge in plasma growth hormone levels. Importantly, research observations highlight that Sermorelin action remains subject to endogenous somatostatin (SRIF) inhibition. When somatostatin levels are high, GHRH-induced cAMP generation is blunted, maintaining the natural pulsatile profile characteristic of physiological growth hormone secretion.
Literature evaluating continuous versus episodic exposure to GHRH(1-29) in culture reveals distinct receptor desensitization kinetics. Prolonged, unpulsed exposure to high concentrations of the ligand leads to GHRH receptor internalization and uncoupling from Gs-alpha, whereas intermittent administration preserves baseline receptor density and functional responsiveness. These findings provide vital framework parameters for designing bioassay protocols.
Within neuroendocrine research, evaluating secretagogues requires contrasting Sermorelin against structurally modified GHRH derivatives and distinct class agonists. Sermorelin represents the native 1-29 sequence without chemical modifications to resist enzymatic degradation, resulting in a short half-life in physiological media (typically under 12 minutes in rat plasma due to rapid cleavage by dipeptidyl peptidase IV).
In contrast, modified GHRH analogs such as CJC-1295 no DAC (also evaluated alongside CJC-1295 research compounds) incorporate specific amino acid substitutions (e.g., D-Ala2, Gln8, Ala15, Leu27) designed to enhance enzymatic stability while retaining GHRHR affinity. Similarly, tesamorelin research compounds feature a trans-3-hexenoic acid group attached to the N-terminal Tyr1 residue, markedly increasing resistance to DPP-IV degradation compared to unmodified GHRH(1-29).
Researchers also compare GHRH agonists with growth hormone secretagogue receptor (GHSR-1a) agonists, such as ipamorelin research compounds. While Sermorelin acts via the GHRHR/cAMP axis, ghrelin mimetics act via the GHSR-1a/phospholipase C axis. Co-administration of GHRH analogs and GHSR agonists in preclinical models frequently demonstrates synergistic secretion responses, confirming distinct but complementary intracellular pathways.
Achieving reproducible experimental results with a sermorelin research compound requires strict adherence to standardized laboratory handling practices. Sermorelin is typically supplied as a lyophilized white powder under vacuum or inert nitrogen gas atmosphere to prevent oxidation and moisture absorption.
For reconstituting lyophilized vials, researchers should utilize sterile laboratory-grade solvents. Standard reconstitution protocols involve adding laboratory-grade sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline depending on downstream assay compatibility. The solvent stream should be directed against the glass wall of the vial rather than directly onto the lyophilized cake, followed by gentle swirl rotation. Mechanical agitation, vortexing, or violent shaking must be avoided, as shear forces can cause peptide aggregation or denaturation.
For cell culture assays requiring specific osmolarity or pH parameters, Sermorelin may be reconstituted in phosphate-buffered saline (PBS, pH 7.4). However, if reconstituted in plain sterile water or PBS without preservatives, aliquots should be used immediately or frozen to prevent bacterial growth and enzymatic degradation.
Lyophilized Sermorelin displays excellent long-term stability when stored under controlled environment conditions. Sealed vials should be stored at -20°C or -80°C in a desiccated environment, shielded from light. Under these conditions, the peptide typically retains analytical purity for up to 24 months.
Once reconstituted into aqueous solution, the chemical degradation rate increases significantly. Deamidation of asparagine (Asn8) and glutamine (Gln16, Gln24) residues, as well as oxidation of the methionine (Met27) residue, represent the primary degradation pathways for GHRH(1-29) in solution. Alkaline pH accelerates deamidation, while trace oxygen or transition metals promote methionine oxidation.
To minimize chemical degradation, reconstituted stock solutions stored at 2°C to 8°C should be used within 7 to 14 days if preserved with bacteriostatic agents. For extended experimental timelines, reconstituted solutions should be rapidly frozen in single-use working aliquots at -80°C. Repeated freeze-thaw cycles must be rigorously avoided, as ice crystal formation can alter secondary peptide structure and reduce active concentration.
In vitro models utilizing primary anterior pituitary cells or immortalized somatotroph lines (such as GH3 or MtT/E cells) frequently employ the sermorelin research compound to map receptor expression and signal transduction cascades. In these assays, researcher teams measure baseline and stimulated cAMP levels using homogeneous time-resolved fluorescence (HTRF) or enzyme-linked immunosorbent assay (ELISA) kits.
In perifusion tissue culture experiments, intact pituitary explants are subjected to automated pulses of Sermorelin-containing media. This design allows investigation of physiological pulse frequency, amplitude, and desensitization dynamics in real time. Quantitative collection of effluent fractions followed by growth hormone radioimmunoassay (RIA) provides precise kinetic curves of somatotroph secretory capacity.
Furthermore, Sermorelin serves as a benchmark agonist in high-throughput screening assays designed to identify small-molecule GHRH receptor modulators, positive allosteric modulators (PAMs), or antagonist compounds. Utilizing consistent high-purity GHRH(1-29) reference standards ensures batch-to-batch assay comparability across longitudinal research studies.
Because minor peptide impurities or synthesis byproducts can significantly skew bioassay outcomes, verifying the quality of any sermorelin research compound is essential prior to trial initiation. Laboratory purchasing teams must demand robust analytical documentation for every production lot.
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the standard method for determining chemical purity. A top-tier manufacturer provides an HPLC chromatogram demonstrating a single major peak corresponding to intact GHRH(1-29), with total relative area purity exceeding 98.0%. Truncated sequences, deletion peptides, and side-reaction products must be quantitatively accounted for in the integration report.
Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF mass spectrometry must accompany HPLC data to confirm correct molecular identity. The observed mass-to-charge ratio (m/z) must match the theoretical monoisotopic mass of Sermorelin (3357.9 Da). Additionally, testing for residual bacterial endotoxins using the Limulus Amebocyte Lysate (LAL) assay is vital for cell culture applications, ensuring endotoxin levels remain strictly under <0.01 EU/μg to prevent non-specific inflammatory signaling in target cell lines.
When sourcing research-grade peptides for institutional or corporate laboratories, verifying supplier infrastructure and quality management systems prevents research downtime and experimental invalidation. PX1 Research manufactures all compounds within modern facilities adherence to stringent ISO 17025 and GMP-compliant quality standards.
Every batch of Sermorelin from PX1 Research undergoes independent third-party analytical verification. Institutional clients receive full, lot-specific Certificates of Analysis (COAs) detailing RP-HPLC purity profiles, mass spectrometry verification, and quantitative LAL endotoxin testing results. Complete lot traceability ensures absolute consistency from bench to bench.
To accommodate various project scales—from preliminary in vitro screens to large-scale comparative research studies—PX1 Research maintains streamlined procurement options via our wholesale lab account portal. All orders ship directly from centralized fulfillment centers in California and Arizona with same-day dispatch for orders placed Monday through Friday.
What is the specific amino acid sequence of the Sermorelin research compound?
Sermorelin corresponds to the amino-terminal 1-29 sequence of human GHRH: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2, with an amidated C-terminus and a molecular weight of 3357.9 Da.
How does Sermorelin differ structurally from CJC-1295 and Tesamorelin?
Sermorelin represents the exact native GHRH(1-29) sequence without modification. CJC-1295 no DAC incorporates four specific amino acid substitutions to resist enzymatic cleavage, while Tesamorelin attaches a trans-3-hexenoic acid group to the N-terminus. Both modified analogs exhibit longer half-lives in biological media compared to unmodified Sermorelin.
What purity standard is required for Sermorelin in laboratory bioassays?
For reliable cellular and preclinical assays, Sermorelin should possess an analytical purity of ≥98% as verified by RP-HPLC, with total endotoxin levels certified below <0.01 EU/μg via LAL testing to prevent non-specific cell activation.
What is the proper solvent for reconstituting Sermorelin for cell culture use?
Lyophilized Sermorelin is typically reconstituted using sterile laboratory-grade bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear mechanical mixing such as vortexing during dissolution.
How should reconstituted Sermorelin solutions be stored to prevent degradation?
Reconstituted Sermorelin solutions should be stored at 2°C to 8°C for short-term use (up to 7-14 days with preservative) or divided into single-use aliquots and stored at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
What receptor pathway does the Sermorelin research compound target?
Sermorelin selectively binds to the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotrophs, activating Gs-alpha G-protein coupling, adenylyl cyclase, intracellular cAMP accumulation, and intracellular calcium mobilization.
Does PX1 Research provide lot-specific Certificates of Analysis for Sermorelin?
Yes. Every lot of Sermorelin supplied by PX1 Research includes a third-party Certificate of Analysis (COA) containing high-resolution RP-HPLC chromatograms, ESI-MS mass identification spectra, and quantitative LAL endotoxin data.
Can Sermorelin be ordered in bulk quantities for institutional research?
Yes. Principal investigators and institutional laboratory buyers can request volume pricing and dedicated supply pipelines through the PX1 Research wholesale lab account program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.